Travere Therapeutics, Inc. (TVTX) shareholders
Close on Nov 17, 2026Market cap $4.82BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Janus Henderson Group PLC | 10,599,660 | 11.90% | 13G (passive) amendment | Sep 30, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (7.70%) | 7,142,482 | 7.70% | 13G (passive) amendment | Jun 30, 2026 |
| Steven Boyd Joint filing with Armistice Capital, LLC (7.52%) | 6,724,000 | 7.52% | 13G (passive) amendment | Sep 30, 2025 |
| BlackRock, Inc. | 6,689,435 | 7.50% | 13G (passive) amendment | Mar 31, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (6.10%) | 5,707,883 | 6.10% | 13G (passive) amendment | Sep 30, 2026 |
| Bank Of America Corp /De/ | 5,439,155 | 5.80% | 13G (passive) | Jun 30, 2026 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (5.50%), Perceptive Life Sciences Master Fund, Ltd. (5.50%) | 4,895,615 | 5.50% | 13G (passive) | Oct 6, 2025 |
| Macquarie Management Holdings Inc Joint filing with Macquarie Group Limited (5.41%), Macquarie Investment Management Business Trust (5.41%) | 4,797,314 | 5.41% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 4,699,424 | 5.09% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TVTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 11,324,191 | 12.01% | $643.30M | New | 0.26% |
| BlackRock, Inc. | 8,020,663 | 8.51% | $455.65M | +228,630 | 0.01% |
| FMR LLC | 7,096,614 | 7.53% | $403.16M | −3,871,353 | 0.02% |
| Bank Of America Corp /De/ | 4,568,341 | 4.85% | $259.53M | +3,223,230 | 0.02% |
| State Street Corp | 4,256,224 | 4.52% | $241.80M | −703,764 | 0.01% |
| Vanguard Capital Management LLC | 4,108,694 | 4.36% | $233.41M | +62,882 | 0.00% |
| Perceptive Advisors LLC | 3,752,574 | 3.98% | $213.18M | −389,977 | 3.20% |
| Nomura Asset Management International Inc. | 2,812,514 | 2.98% | $159.78M | −457,999 | 0.24% |
| Adage Capital Partners Gp, L.L.C. | 2,569,356 | 2.73% | $145.97M | +1,592,356 | 0.20% |
| Geode Capital Management, LLC | 2,371,887 | 2.52% | $134.77M | +2,328 | 0.01% |
| Rock Springs Capital Management LP | 2,179,069 | 2.31% | $123.79M | +701,115 | 6.04% |
| Kynam Capital Management, LP | 2,000,000 | 2.12% | $113.62M | +430,982 | 6.28% |
| Stephens Investment Management Group LLC | 1,875,304 | 1.99% | $106.54M | +76,838 | 1.14% |
| Renaissance Technologies LLC | 1,833,079 | 1.94% | $104.14M | −133,700 | 0.14% |
| Emerald Advisers, LLC | 1,600,886 | 1.70% | $90.95M | +43,690 | 2.14% |
| Armistice Capital, LLC | 1,572,539 | 1.67% | $89.34M | −3,324,878 | 1.09% |
| Two Sigma Investments, LP | 1,565,656 | 1.66% | $88.94M | +57,397 | 0.06% |
| Vanguard Portfolio Management LLC | 1,541,617 | 1.64% | $87.58M | −167,522 | 0.00% |
| Goldman Sachs Group Inc | 1,535,321 | 1.63% | $87.22M | −184,400 | 0.01% |
| Wellington Management Group Llp | 1,533,080 | 1.63% | $87.09M | +510,808 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 319 | 106M | 100.0% | 89 / 121 | 86 / 28 | 32M | 16M |
| Q1 2026 | 261 | 101M | 100.0% | 49 / 90 | 93 / 59 | 20M | 14M |
| Q4 2025 | 278 | 102M | 100.0% | 77 / 90 | 94 / 35 | 21M | 20M |
| Q3 2025 | 238 | 101M | 100.0% | 55 / 74 | 79 / 27 | 18M | 17M |
| Q2 2025 | 212 | 101M | 100.0% | 41 / 75 | 70 / 46 | 17M | 14M |
| Q1 2025 | 218 | 98M | 100.0% | 45 / 89 | 55 / 23 | 19M | 14M |
| Q4 2024 | 197 | 95M | 100.0% | 48 / 74 | 53 / 28 | 24M | 13M |
| Q3 2024 | 178 | 84M | 88.8% | 29 / 62 | 57 / 24 | 22M | 19M |
| Q2 2024 | 174 | 89M | 94.4% | 30 / 72 | 50 / 28 | 12M | 18M |
| Q1 2024 | 175 | 95M | 100.0% | 31 / 65 | 47 / 21 | 13M | 8M |
| Q4 2023 | 165 | 90M | 95.7% | 32 / 58 | 52 / 36 | 21M | 14M |
| Q3 2023 | 169 | 83M | 87.6% | 35 / 66 | 49 / 34 | 22M | 21M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
289 funds held TVTX in Q2 2026, 33% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TVTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,947,890 | 3.13% | $167.47M | 0.01% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 2,580,388 | 2.74% | $121.74M | 0.05% | May 31, 2026 |
| iShares Russell 2000 ETF | 2,294,953 | 2.43% | $130.38M | 0.16% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,130,135 | 2.26% | $121.01M | 1.13% | Jun 30, 2026 |
| Nomura Small Cap Core Fund | 2,086,017 | 2.21% | $98.42M | 1.78% | May 29, 2026 |
| Vanguard Explorer Fund | 1,431,331 | 1.52% | $80.00M | 0.36% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund | 1,413,117 | 1.50% | $80.28M | 1.38% | Jun 30, 2026 |
| Janus Henderson Triton Fund | 1,118,321 | 1.19% | $63.53M | 1.07% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,066,372 | 1.13% | $60.58M | 0.06% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 977,006 | 1.04% | $54.60M | 0.16% | Jul 31, 2026 |
| Fidelity Blue Chip Growth Fund | 913,923 | 0.97% | $51.08M | 0.05% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 825,375 | 0.88% | $46.89M | 0.30% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 798,843 | 0.85% | $37.69M | 0.72% | May 31, 2026 |
| Fidelity Small Cap Growth Fund | 743,290 | 0.79% | $41.54M | 0.47% | Jul 31, 2026 |
| iShares Biotechnology ETF | 640,421 | 0.68% | $36.38M | 0.40% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Eric M. Dube | CHIEF EXECUTIVE OFFICER, Director | 432,886 | 0.46% | Oct 19, 2026 |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | 117,066 | 0.12% | Sep 17, 2026 |
| Elizabeth E. Reed | Chief Legal Officer and GC | 142,889 | 0.15% | Sep 17, 2026 |
| Jula Inrig | EVP, Head of R&D & CMO | 102,491 | 0.11% | Sep 17, 2026 |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | 47,728 | 0.05% | Sep 17, 2026 |
| William E. Rote | Chief Research Officer | 98,197 | 0.10% | Sep 17, 2026 |
| Christopher R. Cline | CHIEF FINANCIAL OFFICER | 87,908 | 0.09% | Sep 17, 2026 |
| Jeffrey A. Meckler | Director | 109,800 | 0.12% | Sep 11, 2026 |
| Gary A. Lyons | Director | 62,400 | 0.07% | Aug 19, 2026 |
| Roy D. Baynes | Director | 46,000 | 0.05% | Jun 16, 2026 |
| Timothy Coughlin | Director | 56,250 | 0.06% | Jun 16, 2026 |
| Brinkley Ruth Williams | Director | 29,750 | 0.03% | May 21, 2026 |
| Suzanne Louise Bruhn | Director | 32,750 | 0.03% | May 21, 2026 |
| Ron Squarer | Director | 39,375 | 0.04% | May 21, 2026 |
| Sandra Poole | Director | 34,000 | 0.04% | May 21, 2026 |
| John A. Orwin | Director | 39,375 | 0.04% | May 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Oct 15, 2026 | Sale(10b5-1 plan) | −78,400 | $55.02 | $4.31M | 432,886 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Oct 15, 2026 | Sale(10b5-1 plan) | −37,270 | $54.20 | $2.02M | 511,286 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Oct 15, 2026 | Sale(10b5-1 plan) | −128,065 | $52.97 | $6.78M | 548,556 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Oct 15, 2026 | Option exercise | +200,000 | $8.93 | $1.79M | 676,621 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Oct 15, 2026 | Option exercise | +43,735 | $26.88 | $1.18M | 476,621 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −101,691 | $64.59 | $6.57M | 439,688 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 17, 2026 | Option exercise | +108,493 | $23.34 | $2.53M | 541,379 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −6,802 | $64.95 | $441.79K | 432,886 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −8,282 | $65.07 | $538.91K | 117,066 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 17, 2026 | Option exercise | +8,282 | $22.40 | $185.52K | 125,348 |
| William E. Rote Chief Research Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −47,746 | $63.61 | $3.04M | 98,197 |
| William E. Rote Chief Research Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −65,104 | $63.12 | $4.11M | 145,943 |
| William E. Rote Chief Research Officer | Sep 16, 2026 | Option exercise | +57,500 | $26.88 | $1.55M | 211,047 |
| William E. Rote Chief Research Officer | Sep 16, 2026 | Option exercise | +55,000 | $15.46 | $850.30K | 153,547 |
| William E. Rote Chief Research Officer | Sep 16, 2026 | Option exercise | +350 | $17.96 | $6.29K | 98,547 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 16, 2026 | Option exercise | +195,841 | $23.34 | $4.57M | 628,727 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 16, 2026 | Sale(10b5-1 plan) | −96,125 | $63.64 | $6.12M | 432,886 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 16, 2026 | Sale(10b5-1 plan) | −99,716 | $63.26 | $6.31M | 529,011 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 16, 2026 | Option exercise | +100,000 | $11.25 | $1.13M | 217,066 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 16, 2026 | Sale(10b5-1 plan) | −79,113 | $63.65 | $5.04M | 117,066 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 16, 2026 | Sale(10b5-1 plan) | −93,604 | $63.25 | $5.92M | 196,179 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 16, 2026 | Option exercise | +17,717 | $26.88 | $476.23K | 289,783 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 16, 2026 | Option exercise | +55,000 | $15.46 | $850.30K | 272,066 |
| Christopher R. Cline CHIEF FINANCIAL OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −1,900 | $63.69 | $121.01K | 87,908 |
| Christopher R. Cline CHIEF FINANCIAL OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −20,735 | $62.61 | $1.30M | 89,808 |
| Christopher R. Cline CHIEF FINANCIAL OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −400 | $65.31 | $26.12K | 87,508 |
| Christopher R. Cline CHIEF FINANCIAL OFFICER | Sep 15, 2026 | Option exercise | +20,000 | $17.44 | $348.80K | 138,016 |
| Christopher R. Cline CHIEF FINANCIAL OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −27,473 | $62.00 | $1.70M | 110,543 |
| Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | Sep 15, 2026 | Option exercise | +1,625 | $20.46 | $33.25K | 47,728 |
| Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −800 | $62.85 | $50.28K | 42,653 |
| Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −4,275 | $62.14 | $265.65K | 43,453 |
| Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −300 | $63.66 | $19.10K | 42,353 |
| Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | Sep 15, 2026 | Option exercise | +1,250 | $22.40 | $28.00K | 46,103 |
| Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | Sep 15, 2026 | Option exercise | +2,500 | $27.50 | $68.75K | 44,853 |
| William E. Rote Chief Research Officer | Sep 15, 2026 | Option exercise | +39,650 | $17.96 | $712.11K | 194,395 |
| William E. Rote Chief Research Officer | Sep 15, 2026 | Option exercise | +39,000 | $25.25 | $984.75K | 154,745 |
| William E. Rote Chief Research Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −270 | $65.31 | $17.63K | 98,197 |
| William E. Rote Chief Research Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −3,000 | $63.65 | $190.95K | 98,467 |
| William E. Rote Chief Research Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −29,021 | $62.66 | $1.82M | 101,467 |
| William E. Rote Chief Research Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −63,907 | $61.99 | $3.96M | 130,488 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −270 | $65.31 | $17.63K | 432,886 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −3,102 | $63.64 | $197.41K | 433,156 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −28,796 | $62.66 | $1.80M | 436,258 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −63,498 | $61.99 | $3.94M | 465,054 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 15, 2026 | Option exercise | +95,666 | $23.34 | $2.23M | 528,552 |
| Jula Inrig EVP, Head of R&D & CMO | Sep 15, 2026 | Sale(10b5-1 plan) | −17,284 | $62.62 | $1.08M | 102,491 |
| Jula Inrig EVP, Head of R&D & CMO | Sep 15, 2026 | Sale(10b5-1 plan) | −1,600 | $63.69 | $101.90K | 100,891 |
| Jula Inrig EVP, Head of R&D & CMO | Sep 15, 2026 | Sale(10b5-1 plan) | −400 | $65.31 | $26.12K | 100,491 |
| Jula Inrig EVP, Head of R&D & CMO | Sep 15, 2026 | Sale(10b5-1 plan) | −25,390 | $62.02 | $1.57M | 119,775 |
| Jula Inrig EVP, Head of R&D & CMO | Sep 15, 2026 | Option exercise | +32,395 | $8.93 | $289.29K | 145,165 |
| Elizabeth E. Reed Chief Legal Officer and GC | Sep 15, 2026 | Option exercise | +37,500 | $15.46 | $579.75K | 142,889 |
| Elizabeth E. Reed Chief Legal Officer and GC | Sep 15, 2026 | Sale(10b5-1 plan) | −21,926 | $62.03 | $1.36M | 120,963 |
| Elizabeth E. Reed Chief Legal Officer and GC | Sep 15, 2026 | Sale(10b5-1 plan) | −13,874 | $62.63 | $868.93K | 107,089 |
| Elizabeth E. Reed Chief Legal Officer and GC | Sep 15, 2026 | Sale(10b5-1 plan) | −300 | $65.31 | $19.59K | 105,389 |
| Elizabeth E. Reed Chief Legal Officer and GC | Sep 15, 2026 | Sale(10b5-1 plan) | −1,400 | $63.69 | $89.17K | 105,689 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 15, 2026 | Option exercise | +39,283 | $26.88 | $1.06M | 181,349 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 15, 2026 | Option exercise | +1,381 | $22.40 | $30.93K | 182,730 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 15, 2026 | Option exercise | +36,526 | $8.93 | $326.18K | 219,256 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −71,938 | $62.05 | $4.46M | 147,318 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −27,421 | $62.59 | $1.72M | 119,897 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Travere Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 455,906 shares on Sep 17, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Eric M. Dube Director, Officer | Oct 15, 2026 | 243,735 | $12.98M | Oct 15, 2026 | Exercise of Stock Options |
| Eric M. Dube Director, Officer | Sep 17, 2026 | 108,493 | $6.89M | Sep 17, 2026 | Exercise of Stock Options |
| Peter Heerma Officer | Sep 17, 2026 | 8,282 | $525.74K | Sep 17, 2026 | Exercise of Stock Options |
| Eric M. Dube Director, Officer | Sep 16, 2026 | 195,841 | $12.24M | Sep 16, 2026 | Exercise of Stock Options |
| Peter Heerma Officer | Sep 16, 2026 | 172,717 | $10.80M | Sep 16, 2026 | Exercise of Stock Options |
| William E. Rote Officer | Sep 16, 2026 | 112,850 | $7.05M | Sep 16, 2026 | Exercise of Stock Options |
| Sandra Calvin Officer | Sep 15, 2026 | 5,375 | $353.62K | Sep 15, 2026 | Exercise of Stock Options |
| Christopher R. Cline Officer | Sep 15, 2026 | 50,508 | $3.32M | Sep 15, 2026 | Exercise of Stock Options |
| Elizabeth E. Reed Officer | Sep 15, 2026 | 39,576 | $2.60M | Sep 15, 2026 | Exercise of Stock Options |
| Eric M. Dube Director, Officer | Sep 15, 2026 | 95,666 | $6.29M | Sep 15, 2026 | Exercise of Stock Options |
| Peter Heerma Officer | Sep 15, 2026 | 102,190 | $6.72M | Sep 15, 2026 | Exercise of Stock Options |
| William E. Rote Officer | Sep 15, 2026 | 96,198 | $6.33M | Sep 15, 2026 | Exercise of Stock Options |
| Jula Inrig Officer | Sep 15, 2026 | 44,674 | $2.94M | Sep 15, 2026 | Exercise of Stock Options |
| Jeffrey A. Meckler Director | Sep 10, 2026 | 20,000 | $1.32M | Sep 10, 2026 | Exercise of Stock Options |
| Gary A. Lyons Director | Aug 18, 2026 | 5,000 | $317.65K | Aug 18, 2026 | Exercise of Stock Options |
See a number that looks wrong?